Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
56.9 USD | -1.22% | +5.09% | -9.00% |
May. 13 | Equities Close Mixed as Markets Weigh Consumer Inflation Survey | MT |
May. 13 | Equities Close Mixed as Markets Parse Consumer Inflation Survey | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.27% | 12.93B | B- | ||
-2.47% | 89.37B | A- | ||
+2.76% | 40.65B | A- | ||
-12.92% | 32.81B | B- | ||
+53.99% | 25B | A | ||
-16.51% | 15.29B | C | ||
-42.60% | 11.61B | B | ||
-12.82% | 11.49B | D+ | ||
+2.77% | 8.98B | B+ | ||
-7.49% | 8.23B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- INCY Stock
- Ratings Incyte Corporation